SCHEMBL486100

SCHEMBL486100

O=C(NC1CCC1)c1ccc2ccccc2c1OCc1csc(-c2ccccc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.44
ATM Q13315 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
PIN1 Q13526 1/20 0.44
LMNA P02545 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 3/20 0.43
SGMS2 Q8NHU3 1/20 0.43
NPC1 O15118 3/20 0.42
CNR2 P34972 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TSHR P16473 2/20 0.42
CNR1 P21554 2/20 0.42
HTT P42858 1/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL27713038 0.96 PIN1 (0.42) RAB9AATML3MBTL1KDM4EGAA
SCHEMBL485671 0.88 KDM4E (0.48) RAB9AKDM4ELMNAALDH1A1MEN1
Formic Acid SCHEMBL27713042 0.85 SCN9A (0.43) RAB9AATML3MBTL1KDM4EGAA
SCHEMBL485245 0.82 CXCR2 (0.58) RAB9AATML3MBTL1KDM4EGAA
SCHEMBL485572 0.82 CXCR2 (0.51) RAB9AATML3MBTL1KDM4EGAA
SCHEMBL27713037 0.81 CXCR2 (0.44) RAB9AATML3MBTL1KDM4EGAA
Formic Acid SCHEMBL27693263 0.80 MEN1 (0.57) RAB9AL3MBTL1KDM4EALDH1A1MEN1
SCHEMBL10289497 0.78 RAB9A (0.44) RAB9AATML3MBTL1KDM4EGAA
Formic Acid SCHEMBL27693208 0.78 ALOX5AP (0.51) RAB9AKDM4EGAALMNAALDH1A1
SCHEMBL485544 0.76 CXCR2 (0.46) RAB9AATML3MBTL1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836158-B1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-02-01 EP claimed